Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia.
ADCC, antibody-dependent cell-mediated cytotoxicity
CEP, chronic eosinophilic pneumonia
CT, computed tomography
Chronic eosinophilic pneumonia
Cryobiopsy
GGO, ground-glass opacity
IL-5, interleukin 5
Interleukin-5 receptor α monoclonal antibody
OCS, oral corticosteroid
Oral corticosteroid
Side effects
Journal
Respiratory medicine case reports
ISSN: 2213-0071
Titre abrégé: Respir Med Case Rep
Pays: England
ID NLM: 101604463
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
03
2020
revised:
18
04
2020
accepted:
19
04
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
7
5
2020
Statut:
epublish
Résumé
Chronic eosinophilic pneumonia (CEP) is an eosinophilic inflammatory disease of unknown etiology, and oral corticosteroid (OCS) is commonly used for its treatment. Approximately half of CEP cases relapse secondary to reduction or termination of OCS. A 43-year-old woman visited our hospital because of a chronic cough and abnormal chest X-ray findings. She was diagnosed with CEP because of marked eosinophilia, as well as eosinophilic infiltrates in cryobiopsy samples. After initiation of OCS treatment, her symptoms disappeared with a decrease in peripheral blood eosinophil counts and the amelioration of abnormal infiltrative shadows on chest X-ray. However, symptoms reappeared after OCS termination, including a recurrence of eosinophilia and appearance of fresh abnormal shadows on chest X-ray. Because she refused readministration of OCS because of side effects such as appetite enhancement and moon face in last treatment course, we administered her a single dose of benralizumab. Her symptoms and peripheral eosinophil counts were markedly ameliorated 1 week after benralizumab administration. The marked amelioration in abnormal shadows on chest X-ray were maintained 2 weeks after benralizumab administration. She had no relapse of CEP for almost 6 months after benralizumab administration. Our experience with this case suggests that a single dose of benralizumab may be a treatment option for relapsed CEP cases or those with side effects of long-term OCS therapy.
Identifiants
pubmed: 32373456
doi: 10.1016/j.rmcr.2020.101062
pii: S2213-0071(20)30094-0
pii: 101062
pmc: PMC7193122
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101062Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
All authors have no conflicts of interest to disclose.
Références
Respir Med. 2016 Feb;111:21-9
pubmed: 26775606
J Allergy Clin Immunol. 2010 Jun;125(6):1344-1353.e2
pubmed: 20513525
Medicine (Baltimore). 1998 Sep;77(5):299-312
pubmed: 9772920
Eur Respir J. 1997 Feb;10(2):286-91
pubmed: 9042622
Allergol Int. 2019 Oct;68(4):413-419
pubmed: 31253537
Nat Rev Drug Discov. 2013 Feb;12(2):117-29
pubmed: 23334207
Cytokine. 2017 Oct;98:59-70
pubmed: 28863833
J Allergy Clin Immunol. 2013 Nov;132(5):1086-1096.e5
pubmed: 23866823
Respir Med Case Rep. 2019 Feb 19;26:292-295
pubmed: 30859062
Chest. 1993 Jan;103(1):162-5
pubmed: 8031327
J Allergy Clin Immunol. 2010 Jun;125(6):1237-1244.e2
pubmed: 20513521